Cargando…

Therapeutic strategies for asymptomatic upper urinary tract urothelial carcinoma

INTRODUCTION: Upper urinary tract epithelial carcinoma (UTUC) and bladder cancer are both sources of urinary epithelial cell. In our previous study of asymptomatic bladder tumors, we found that most of these tumors could be resected through the urethra without radical surgery. This study analyzed th...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Deng, Hong, Yun, Yang, Zesong, Ye, Liefu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481439/
https://www.ncbi.nlm.nih.gov/pubmed/37680741
http://dx.doi.org/10.5114/wiitm.2022.123307
_version_ 1785101974133276672
author Lin, Deng
Hong, Yun
Yang, Zesong
Ye, Liefu
author_facet Lin, Deng
Hong, Yun
Yang, Zesong
Ye, Liefu
author_sort Lin, Deng
collection PubMed
description INTRODUCTION: Upper urinary tract epithelial carcinoma (UTUC) and bladder cancer are both sources of urinary epithelial cell. In our previous study of asymptomatic bladder tumors, we found that most of these tumors could be resected through the urethra without radical surgery. This study analyzed the treatment strategies for asymptomatic UTUC. AIM: To investigate the clinicopathological features and surgical methods of these patients, thus choosing appropriate surgical treatment. MATERIAL AND METHODS: 136 patients with UTUC were recruited, of whom 21 patients with asymptomatic UTUC were group A, and 115 UTUC patients with hematuria or low back pain were group B. The clinicopathological features, oncologic outcomes, and surgical methods of patients were evaluated. RESULTS: Radical resection was the main surgical treatment which was included (group A 80.95%, group B 90.43%). Other patients were treated with kidney-retaining surgery. No statistically significant difference was observed in the pathological stage and grade between groups A and B (p > 0.05). During a median follow-up period of 44.3 months, tumor-specific mortality of group A was 7.14%, and that of group B was 5.10%. In the same period, 106 patients with asymptomatic bladder tumor were recruited: 31 patients of them had asymptomatic bladder urothelial carcinoma. The asymptomatic UTUC group had a higher stage and grade of clinicopathological features than the asymptomatic bladder urothelial carcinoma group (p < 0.001). CONCLUSIONS: The principle of asymptomatic UTUC treatment is the same as that of symptomatic UTUC. Risk stratification should be carried out according to clinical staging and other parameters, and the corresponding surgical treatment should be selected.
format Online
Article
Text
id pubmed-10481439
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-104814392023-09-07 Therapeutic strategies for asymptomatic upper urinary tract urothelial carcinoma Lin, Deng Hong, Yun Yang, Zesong Ye, Liefu Wideochir Inne Tech Maloinwazyjne Original Paper INTRODUCTION: Upper urinary tract epithelial carcinoma (UTUC) and bladder cancer are both sources of urinary epithelial cell. In our previous study of asymptomatic bladder tumors, we found that most of these tumors could be resected through the urethra without radical surgery. This study analyzed the treatment strategies for asymptomatic UTUC. AIM: To investigate the clinicopathological features and surgical methods of these patients, thus choosing appropriate surgical treatment. MATERIAL AND METHODS: 136 patients with UTUC were recruited, of whom 21 patients with asymptomatic UTUC were group A, and 115 UTUC patients with hematuria or low back pain were group B. The clinicopathological features, oncologic outcomes, and surgical methods of patients were evaluated. RESULTS: Radical resection was the main surgical treatment which was included (group A 80.95%, group B 90.43%). Other patients were treated with kidney-retaining surgery. No statistically significant difference was observed in the pathological stage and grade between groups A and B (p > 0.05). During a median follow-up period of 44.3 months, tumor-specific mortality of group A was 7.14%, and that of group B was 5.10%. In the same period, 106 patients with asymptomatic bladder tumor were recruited: 31 patients of them had asymptomatic bladder urothelial carcinoma. The asymptomatic UTUC group had a higher stage and grade of clinicopathological features than the asymptomatic bladder urothelial carcinoma group (p < 0.001). CONCLUSIONS: The principle of asymptomatic UTUC treatment is the same as that of symptomatic UTUC. Risk stratification should be carried out according to clinical staging and other parameters, and the corresponding surgical treatment should be selected. Termedia Publishing House 2022-12-22 2023-06 /pmc/articles/PMC10481439/ /pubmed/37680741 http://dx.doi.org/10.5114/wiitm.2022.123307 Text en Copyright © 2023 Sekcja Wideochirurgii TChP https://creativecommons.org/licenses/by-nc-sa/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/ (https://creativecommons.org/licenses/by-nc-sa/4.0/) )
spellingShingle Original Paper
Lin, Deng
Hong, Yun
Yang, Zesong
Ye, Liefu
Therapeutic strategies for asymptomatic upper urinary tract urothelial carcinoma
title Therapeutic strategies for asymptomatic upper urinary tract urothelial carcinoma
title_full Therapeutic strategies for asymptomatic upper urinary tract urothelial carcinoma
title_fullStr Therapeutic strategies for asymptomatic upper urinary tract urothelial carcinoma
title_full_unstemmed Therapeutic strategies for asymptomatic upper urinary tract urothelial carcinoma
title_short Therapeutic strategies for asymptomatic upper urinary tract urothelial carcinoma
title_sort therapeutic strategies for asymptomatic upper urinary tract urothelial carcinoma
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481439/
https://www.ncbi.nlm.nih.gov/pubmed/37680741
http://dx.doi.org/10.5114/wiitm.2022.123307
work_keys_str_mv AT lindeng therapeuticstrategiesforasymptomaticupperurinarytracturothelialcarcinoma
AT hongyun therapeuticstrategiesforasymptomaticupperurinarytracturothelialcarcinoma
AT yangzesong therapeuticstrategiesforasymptomaticupperurinarytracturothelialcarcinoma
AT yeliefu therapeuticstrategiesforasymptomaticupperurinarytracturothelialcarcinoma